ArticleRMD open2025
Development of an enzyme-linked immunosorbent assay for the efficient detection of autoantibodies against nuclear valosin-containing protein-like protein (NVL) 2 using its manipulated cDNA.
Article in RMD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The clinical utility of autoantibodies in systemic sclerosis: a review with a focus on cohort differences and standardization.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAntinuclear valosin-containing protein-like protein (NVL) antibodies have been detected only in systemic sclerosis (SSc) patients, and diverse comorbidities have been reported in anti-NVL antibody-positive SSc patients. Any relationship between antibodies against NVL1, a minor isoform of NVL, and the clinical symptoms also remains unclear. To clarify the clinical features of anti-NVL2 antibody-positive patients, we developed an ELISA for measuring antibodies against NVL2, a major target of autoantibodies against NVL.
methodsSera from 1676 patients with various conditions were included. 167 anti-nucleolar antibody (ANoA)-positive sera, 120 ANoA-negative sera and 17 healthy control sera were examined by an ELISA that uses the recombinant protein of NVL2 derived from its gene-manipulated complementary DNA clone (modified NVL2 (mNVL2)).
results18 ANoA-positive sera subjected to indirect immunofluorescence (IIF) were positive for anti-mNVL2 ELISA. Although one ANoA-negative serum was judged false positive in our anti-mNVL2 ELISA, the above 18 anti-mNVL2 ELISA-positive sera were confirmed to be positive for anti-NVL2 antibodies by immunoprecipitation-Western blotting. Anti-NVL2 antibodies were detected in 17.0% of homogeneous nucleolar (AC-8) patterns in IIF. Six SSc patients had anti-NVL2 antibodies, whereas five with idiopathic interstitial pneumonia and seven with other diseases had anti-NVL2 antibodies. Anti-mNVL2 ELISA titres were significantly higher in the anti-NVL2 antibody-positive SSc patients than in the anti-NVL2 antibody-positive non-SSc patients (p<0.042).
conclusionsWe found more anti-NVL2 antibody-positive cases than any previous study, as far as we know. Our ELISA, which showed an association between titres of these antibodies and SSc diagnosis, promises to expand knowledge about anti-NVL2 antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.